France OKs Early Access To Tecentriq For SCLC Pending EU Approval
Executive Summary
Tecentriq has become the second authorized medicine to be made available for an unapproved indication under modifications to France’s early access program. Patients with small cell lung cancer can now be given the product pending EU approval of its use in this condition.
You may also be interested in...
Roche Wins Two French Early Access Programs In Breast Cancer
Roche's cancer drugs, Tecentriq (atezolizumab) and Kadcyla (trastuzumab emtansine), are the latest products to be granted French temporary use authorizations for new, as yet unapproved indications.
French Agency To Boost EU Role & Open Up To Outside World
France’s medicines and medical devices regulator wants to build up its role in the EU regulatory system, make its inner workings more accessible to stakeholders and the outside world, and improve the way it deals with medicine shortages.
EU OK To Tecentriq-Avastin Combo In NSCLC Includes EGFR-Mutant, ALK-Positive Patients
EU approval of Tecentriq and Avastin together with chemo for the first-line treatment of metastatic non-squamous NSCLC is a positive advance for Roche, but analysts say the combo has a long way to go still to catch up with Merck & Co’s Keytruda combination.